Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma

Loading news article.

Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma | WAPE

Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma

Article summary

Related companies

Comments —